EmsanaRx Is Changing Its Name to AffirmedRx
EmsanaRx, the upstart pharmacy benefit manager (PBM) that says its priority is public health, announced yesterday that it is changing its name to AffirmedRx.
EmsanaRx was launched in late 2021 as project of Emsana Health, an independent company established by The Purchaser Business Group on Health, a coalition of large employers. Emsana Health bills itself as an “innovation studio” for healthcare.
According to a press release Emsana Health sold its equity stake back EmsanaRx.
The press release says that AffirmedRx will continue EmsanaRx’s work “to create a completely unconflicted pharmacy benefit manager that all large self-funded employers can be proud to collaborate with.”
Greg Baker, CEO of EmsanaRx, is staying CEO of AffirmedRx, which has adopted “patients over profits” as it tagline. Like EmsanaRx, AffirmedRex is a public benefit corporation, a legal status that allows the company to prioritize public good and not just shareholders.
Baker says in the new name reflects “our commitment to forging new paths with members to deliver innovation and flexibility.”
Unrealistic Portrayals of Cardiac Arrest in Contemporary Film | ACC 2025
March 31st 2025Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Winrevair Reduced Risk of Morbidity and Mortality by 76% in PAH | ACC 2025
March 31st 2025In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension.
Read More
Clopidogrel Beat Aspirin in Preventing Heart Attacks After PCI | ACC 2025
March 31st 2025Clopidogrel monotherapy may be an alternative to aspirin for prevention of cardiac events in high-risk patients after percutaneous coronary intervention, according to a new study presented at ACC 2025.
Read More
